NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies
Updated: Feb 10
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT03424603
Official Title: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
First Posted : February 7, 2018
Click here to see details on ClinicalTrials.gov
STRO-001-BCM1
Drug: STRO-001
intravenous antibody drug conjugate
Anti-CD74 Antibody-drug Conjugate STRO-001 (Code C148066)
ADC STRO-001
Anti-CD74 ADC STRO-001
Anti-CD74 Antibody-drug Conjugate STRO-001
SP7675
STRO-001
Locations
United States, Alabama
United States, Arizona
United States, California
United States, Colorado
United States, Georgia
United States, Indiana
United States, Kansas
United States, Maryland
United States, Michigan
United States, New York
United States, Oregon
United States, Texas
United States, Virginia
United States, West Virginia
United States, Wisconsin
Comments